Cost effectiveness of preventive interventions in type 2 diabetes mellitus: A systematic literature review

PharmacoEconomics

Volumn 24, Issue 5, 2006, Pages 425-441

  Vijgen, Sylvia M C ^a   Hoogendoorn, Mirjam ^a   Baan, Caroline A ^a   De Wit, G Ardine ^a   Limburg, Wien ^a   Feenstra, Talitha L ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTILIPEMIC AGENT; ATENOLOL; CAPTOPRIL; DOXAZOSIN; GLIBENCLAMIDE; HYPERGLYCEMIC AGENT; INSULIN; IRBESARTAN; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PRAVASTATIN; SIMVASTATIN; SULFONYLUREA; TETRAHYDROLIPSTATIN; TROGLITAZONE;

BLOOD PRESSURE REGULATION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DIABETES EDUCATION; DIABETIC HYPERTENSION; DIET; DYSLIPIDEMIA; EARLY DIAGNOSIS; ECONOMIC EVALUATION; EXERCISE; FOLLOW UP; HEALTH CARE COST; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; INSULIN TREATMENT; LIFESTYLE; LOW CALORY DIET; MEDICAL LITERATURE; MEDICAL RECORD; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVENTIVE HEALTH SERVICE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROPHYLAXIS; PUBLICATION; REVIEW; SCREENING; SECONDARY PREVENTION; SITTING; SYSTEMATIC REVIEW; WEIGHT REDUCTION;

COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DIET; EXERCISE; HEALTH CARE COSTS; HUMANS; HYPERGLYCEMIA; HYPERTENSION; OBESITY; PATIENT EDUCATION; PREVENTIVE HEALTH SERVICES;

EID: 33646821678     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200624050-00002     Document Type: Review

References (97)

1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27 (5): 1047-53
2. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: the Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998 Apr; 21 (4): 518-24
3. Borch-Johnsen K, Lauritzen T, Glumer C, et al. Screening for type 2 diabetes: should it be now? Diabet Med 2003; 20 (3): 175-81
4. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2004; 27 Suppl. 1: S11-4
5. van Os N, Niessen LW, Koopmanschap MA, et al. Detailed analysis of the societal costs of diabetes mellitus [in Dutch]. Ned Tijdschr Geneeskd 2000; 144 (18): 842-6
6. Raikou M, McGuire A. The economics of screening and treatment in type 2 diabetes mellitus. Pharmacoeconomics 2003; 21 (8): 543-64
7. Klonoff DC, Schwartz DM. An economic analysis of interventions for diabetes. Diabetes Care 2000; 23 (3): 390-404
8. Zhang P, Engelgau M, Norris SL. Application of economic analysis to diabetes and diabetes care. Ann Intern Med 2004; 140 (11): 972-7
9. Clarke P, Gray A, Adler A, et al. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51). Diabetologia 2001; 44 (3): 298-304
10. Gray A, Clarke P, Raikou M, et al. An economic evaluation of atenolol vs captopril in patients with type 2 diabetes (UKPDS 54). Diabet Med 2001; 18 (6): 438-44
11. UK Prospective Diabetes Study Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ 1998 Sep 12; 317 (7160): 720-6
12. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996 Aug; 313: 275-83
13. O'Connor PJ, Rush WA, Cherney LM, et al. Screening for diabetes mellitus in high-risk patients: cost, yield, and acceptability. Eff Clin Pract 2001; 4 (6): 271-7
14. Law AV, Pathak DS, Segraves AM, et al. Cost-effectiveness analyses of the conversion of patients with non-insulin-dependent diabetes mellitus from glipizide to glyburide and of the accompanying pharmacy follow-up clinic. Clin Ther 1995; 17 (5): 977-87
15. Trento M, Passera P, Bajardi M, et al. Lifestyle intervention by group care prevents deterioration of type II diabetes: a 4-year randomized controlled clinical trial. Diabetologia 2002; 45 (9): 1231-9
16. Glasgow RE, Chance PAL, Toobert DJ, et al. Long-term effects and costs of brief behavioural dietary intervention for patients with diabetes delivered from the medical office. Patient Educ Couns 1997; 32 (3): 175-84
17. The Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care 2003; 26 (9): 2518-23
18. Gray A, Raikou M, McGuire A, et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomized controlled trial (UKPDS 41). The United Kingdom Prospective Diabetes Study (UKPDS) Group. BMJ 2000; 320: 1373-8
19. Jonsson B, Hansson L, Stalhammar NO. Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. J Intern Med 2003; 253 (4): 472-80
20. Brown RR. Cost-effectiveness and clinical outcomes of metformin or insulin add-on therapy in adults with type 2 diabetes. Am J Health Syst Pharm 1998; 55 (24 Suppl. 4): S24-7
21. Souchet T, Durand Zaleski I, Hannedouche T, et al. An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France. Diabetes Metab 2003; 29 (1): 29-35
22. Hoerger TJ, Harris R, Hicks KA, et al. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med 2004; 140 (9): 689-99
23. Segal L, Dalton AC, Richardson J. Cost-effectiveness of the primary prevention of non-insulin dependent diabetes mellitus. Health Promot Int 1998; 13 (3): 197-209
24. Elliott WJ, Weir DR, Black HR. Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients: Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 2000; 160 (9): 1277-83
25. Gozzoli V, Palmer AJ, Brandt A, et al. Economic and clinical impact of alternative disease management strategies for secondary prevention in type 2 diabetes in the Swiss setting. Schweiz Med Wochenschr 2001; 131 (21-22): 303-10
26. Palmer AJ, Roze S, Valentine WJ, et al. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom. Clin Ther 2004; 26: 304-21
27. The CDC Diabetes Cost-Effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 2002; 287 (19): 2542-51
28. Jonsson B, Cook JR, Pedersen TR. The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia 1999; 42 (11): 1293-301
29. Lamotte M, Annemans L, Lefever A, et al. A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients. Diabetes Care 2002; 25 (2): 303-8
30. Coyle D, Palmer AJ, Tam R. Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada. Pharmacoeconomics 2002; 20 Suppl. 1: 31-42
31. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM: II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997; 20 (5): 735-44
32. Maetzel A, Ruof J, Covington M, et al. Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus. Pharmacoeconomics 2003; 21 (7): 501-12
33. Henriksson F. Applications of economic models in healthcare: the introduction of pioglitazone in Sweden. Pharmacoeconomics 2002; 20 Suppl. 1: 43-53
34. Palmer AJ, Sendi PP, Spinas GA. Applying some UK Prospective Diabetes Study results to Switzerland: the cost-effectiveness of intensive glycaemic control with metformin versus conventional control in overweight patients with type-2 diabetes. Schweiz Med Wochenschr 2000; 130 (27-28): 1034-40
35. Salas M, Ward A, Caro J. Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus. Clin Ther 2002; 24 (10): 1690-705
36. Caro JJ, Klittich WS, Raggio G, et al. Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes. Clin Ther 2000; 22 (1): 116-27
37. Almbrand B, Johannesson M, Sjostrand B, et al. Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus: results from the DIGAMI study. Eur Heart J 2000; 21 (9): 733-9
38. Neeser K, Lubben G, Siebert U, et al. Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a German statutory healthcare perspective. Pharmacoeconomics 2004; 22 (5): 321-41
39. Casciano J, Doyle J, Casciano R, et al. The cost-effectiveness of doxazosin for the treatment of hypertension in type II diabetic patients in the UK and Italy. Int J Clin Pract 2001; 55 (2): 84-92
40. Rodby RA, Chiou CF, Borenstein J, et al. The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. Clin Ther 2003; 25 (7): 2102-19
41. Grover SA, Coupal L, Zowall H, et al. How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? Diabetes Care 2001; 24 (1): 45-50
42. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group [published erratum appears in BMJ 1999 Jan 2; 318 (7175): 29]. BMJ 1998 Sep 12; 317 (7160): 703-13
43. Grimm RH, Flack JM, Grandits GA, et al. Long-term effects on plasma lipids of diet and drugs to treat hypertension. JAMA 1996; 275: 1549-56
44. Anderson KM, Odell PM, Wilson PWF, et al. Cardiovascular disease risk profiles. Am Heart J 1990; 121: 293-8
45. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published erratum appears in Lancet 1999 Aug 14; 354 (9178): 602]. Lancet 1998 Sep 12; 352 (9131): 837-53
46. The West of Scotland Coronary Prevention Study Group. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. Am J Cardiol 1997 Mar 15; 79 (6): 756-62
47. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy: IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1989 Feb; 107 (2): 237-43
48. Ballard DJ, Melton LJ III, Dwyer MS, et al. Risk factors for diabetic retinopathy: a population-based study in Rochester, Minnesota. Diabetes Care 1986 Jul-Aug; 9 (4): 334-42
49. The Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial [published erratum appears in JAMA 1997 Jul 2; 278 (1): 25]. JAMA 1996 Nov 6; 276 (17): 1409-15
50. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998; 351: 1755-62
51. Humphrey LL, Ballard DJ, Frohnert PP, et al. Chronic renal failure in non-insulin-dependent diabetes mellitus: a population-based study in Rochester, Minnesota. Ann Intern Med 1989 Nov 15; 111 (10): 788-96
52. Taylor TN, Davis PH, Torner JC, et al. Lifetime cost of stroke in the United States. Stroke 1996 Sep; 27 (9): 1459-66
53. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease: part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990 Apr 7; 335 (8693): 827-38
54. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study. Diabetes Care 1998 Aug; 21 (8): 1288-94
55. Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000 May 8; 160 (9): 1321-6
56. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352 (9131): 854-65
57. Koskinen P, Manttari M, Manninen V, et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992 Jul; 15 (7): 820-5
58. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type diabetes (UKPDS 35): prospective observational study. BMJ 2000 Aug 12; 321 (7258): 405-12
59. Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med 2000 Sep; 248 (3): 245-54
60. Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 2002 Nov; 4 (6): 415-23
61. Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2002 Jun; 25 (6): 1033-41
62. Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002 Jul; 25 (7): 1123-8
63. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin: Diabetes Prevention Program Research Group. N Engl J Med 2002 Feb 7; 346 (6): 393-403
64. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes: Collaborative Study Group. N Engl J Med 2001 Sep 20; 345 (12): 851-60
65. Rodby RA, Rohde RD, Clarke WR, et al. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group. Nephrol Dial Transplant 2000 Apr; 15 (4): 487-97
66. Balkau B, Eschwege E, Papoz L, et al. Risk factors for early death in non-insulin dependent diabetes and men with known glucose tolerance status. BMJ 1993; 307 (6899): 295-9
67. Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus [published erratum appears in Diabetologia 1987; 30 (5): 364]. Diabetologia 1987; 30 (3): 123-31
68. Simons LA, McCallum J, Freidlander Y, et al. Diabetes, mortality and coronary heart disease in the prospective Dubbo study of Australian elderly. Aust N Z J Med 1996; 26 (1): 66-74
69. Drenick EJ, Bale GS, Seltzer F, et al. Excessive mortality and causes of death in morbidly obese men. JAMA 1980; 243 (5): 443-5
70. Manson JE, Stampfer MJ, Hennekens CH, et al. Body weight and longevity: a reassessment. JAMA 1987; 257 (3): 353-8
71. Rissanen A, Heliovaara M, P Knekt, et al. Risk of disability and mortality due to overweight in a Finnish population. BMJ 1990; 301 (6756): 835-7
72. Body weight and mortality: a 27-year follow-up of middle aged men. JAMA 1993; 270 (23): 2823-8
73. Eriksson KF, Lindgarde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise: the 6-year Malmo feasibility study. Diabetologia 1991 Dec; 34 (12): 891-8
74. Australian Bureau of Statistics (1995). Deaths, Australia (1994). Catalogue No. 3302.0. Australian Government Publishing Service, Canberra
75. Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999 Dec 13-27; 159 (22): 2661-7
76. Grover SA, Coupal L, Paquet S, et al. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events. Arch Intern Med 1999 Mar 22; 159 (6): 593-600
77. Grover SA, Paquet S, Levinton C, et al. Estimating the benefits of modifying risk factors of cardiovascular disease: a comparison of primary vs secondary prevention. Arch Intern Med 1998 Mar 23; 158 (6): 655-62
78. Grover SA, Palmer CS, Coupal L. Serum lipid screening to identify high-risk individuals for coronary death: the results of the Lipid Research Clinics prevalence cohort. Arch Intern Med 1994 Mar 28; 154 (6): 679-84
79. Horton ES, Clinkingbeard C, Gatlin M, et al. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000 Nov; 23 (11): 1660-5
80. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993 Sep 30; 329 (14): 977-86
81. Horton ES, Whitehouse F, Ghazzi MN, et al. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes: the Troglitazone Study Group. Diabetes Care 1998 Sep; 21 (9): 1462-9
82. Palmer AJ, Weiss C, Sendi PP, et al. The cost-effectiveness of different management strategies for type I diabetes: a Swiss perspective. Diabetologia 2000 Jan; 43 (1): 13-26
83. Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000 Nov; 23 (11): 1605-11
84. Johansen K. Efficacy of metformin in the treatment of NIDDM: meta-analysis. Diabetes Care 1999 Jan; 22 (1): 33-7
85. Hermann LS, Schersten B, Bitzen PO, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: a double-blind controlled study. Diabetes Care 1994 Oct; 17 (10): 1100-9
86. Matthews DR, Cull CA, Stratton IM, et al. UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) group. Diabet Med 1998 Apr; 15 (4): 297-303
87. Henriksson F, Agardh CD, Berne C, et al. Direct medical costs for patients with type 2 diabetes in Sweden. J Intern Med 2000 Nov; 248 (5): 387-96
88. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998 Sep 12; 317 (7160): 713-20
89. Bundesamt fur Statistik. Stebetafeln fur die Schweiz 1988/1993. Bern: 1996
90. Arbeitsgruppe der Schweizerischen Diabetes-Stiftung. Die St. Vincent-Deklaration: eine Umfrage zur Diabetiker-Betreuung in der Schweiz. Schweizerische Aerztezeitung 1996; 77: 668-75
91. Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001 Jul; 111 (1): 10-7
92. Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000 Dec; 22 (12): 1395-409
93. Piehlmeier W, Renner R, Schramm W, et al. Screening of diabetic patients for microalbuminuria in primary care: the PROSIT-Project. Proteinuria Screening and Intervention. Exp Clin Endocrinol Diabetes 1999; 107 (4): 244-51
94. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995 Jul; 26 (1): 57-65
95. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) study group. BMJ 1997 May 24; 314 (7093): 1512-5
96. CDC Diabetes Cost-Effectiveness Study Group. The cost-effectiveness of screening for type 2 diabetes. JAMA 1998; 280 (20): 1757-63
97. Welte R, Feenstra T, Jager H, et al. A decision chart for assessing and improving the transferability of economic results between countries. Pharmacoeconomics 2004; 22 (13): 857-76